Abstract Library

#4515 Prognostic factors for survival in patients with metastatic small intestinal neuroendocrine tumours undergoing primary tumour resection

Introduction: Although guidelines recommend primary tumour resection in metastatic small intestinal neuroendocrine tumours (SI-NETs) to manage symptoms and complications, the survival benefit and optimal surgical approach remain unclear.

Conference:

Presenting Author:

Authors: Dell' Unto E, Ogunbiyi O, Mirnezami R, Malam Y, Yasin Y,

Keywords: Small Intestinal Neuroendocrine Tumour, surgery, midgut carcinoid,

#4507 Biliary complications for metastatic patients with neuroendocrine tumours of the pancreatic head and their influence on survival: Is it necessary to change the current management?

Introduction: Neuroendocrine tumours of the pancreatic head (NETPH) can be associated with local complications. At the metastatic stage, surgery of the primary tumour (PT) is not a standard of care. But the biliary complications (BC) due to the untreated NETPH may complicate the management and deteriorate the prognosis.

Conference:

Presenting Author: Ujlaki G

Authors: Ujlaki G, Fernandez de Sevilla E, Moog S, Lamartina L, Hadoux J,

Keywords: neuroendocrine, pancreatic head, metastatic, biliary complications,

#3857 The use of quantitative contrast-enhanced endoscopic ultrasound in the evaluation of pancreatic neuroendocrine tumors – Can we move from quality to quantity? A proof-of-concept study

Introduction: Contrast-enhanced EUS (CE-EUS) is a helpful tool for the diagnosis of pancreatic focal lesions, as pancreatic cancer (PC) and pancreatic neuroendocrine tumor (pNEN). The enhancement of the lesion after contrast medium injection is usually assessed qualitatively and arbitrarily by the endosonographer. Dedicated software has recently been developed to obtain an unbiased quantitative assessment using perfusion parameters.

Conference:

Presenting Author: Tacelli M

Authors: Tacelli M, Bina N, Capurso G, Zaccari P, Petrone M,

Keywords: CE-EUS, pNEN, artificial intelligence, pancreatic cancer, prediction,

#3778 Biological behaviour and response to treatment of neuroendocrine ovarian metastases

Introduction: Neuroendocrine ovarian metastases (NOM) predominantly derive from midgut neuroendocrine tumors (NETs) and develop in about 25% of female patients. Little is known of the treatment response of NOM.

Conference:

Presenting Author:

Authors: Mulders M, de Lussanet de La Sablonière Q, van Velthuysen M, Hofland J, de Herder W,

Keywords: neuroendocrine, ovary, PRRT, SSA, oophorectomy, tumor, growth, rate, PFS, OS,

#3514 DLL3 expression and clinico-pathological data in 247 patients with NEN

Introduction: Delta-like protein 3 (DLL3) is currently under clinical investigation as a potential therapeutic target in small cell neuroendocrine lung cancer. Characterization of the levels and patterns of DLL3 expression in other neuroendocrine neoplasms (NEN) is limited.

Conference:

Presenting Author: Clausen M

Authors: Clausen M, Federspiel B, Carstensen F, Suppli M, Kjaer A,

Keywords: DLL3, high-grade NEN,